The North America Transdermal Patches Market would witness market growth of 3.9% CAGR during the forecast period (2023-2030). In the year 2019, the North America market's volume surged to 10,98,722.8 thousand units, showcasing a growth of 3.6% (2019-2022).
The market has witnessed remarkable growth and innovation in recent years, reshaping the landscape of pharmaceutical drug delivery. This market, driven by patient convenience, sustained drug release, and improved therapeutic outcomes, has become a pivotal component of the healthcare sector. Adopting transdermal patches has steadily risen across various healthcare domains, driven by several factors contributing to their attractiveness to healthcare providers and patients.
The aging population has also played a significant role in adopting transdermal patches. As the prevalence of chronic diseases rises among the elderly, there is a growing demand for therapeutic options that are not only effective but also user-friendly. These offer a solution to these demographic challenges by providing a convenient and patient-friendly method of drug administration. In addition to the ease of use, these provide controlled and sustained drug release, improving patient compliance and therapeutic outcomes.
North America is witnessing a significant increase in the incidence of chronic diseases such as diabetes, cardiovascular diseases, and chronic pain conditions. The aging population, sedentary lifestyles, and dietary patterns contribute to the higher prevalence of these conditions. Cardiovascular diseases, including hypertension and angina, are prevalent in North America. Therefore, growing chronic disease prevalence in North America is expected to help expand the regional market.
The US market dominated the North America Transdermal Patches Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,134.9 million by 2030. The Canada market is experiencing a CAGR of 6.2% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.3% during (2023 - 2030).
Based on End User, the market is segmented into Homecare Settings and Hospitals & Clinics. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on Adhesive Type, the market is segmented into Acrylic Adhesives, Silicone Adhesives, Hydrogel Adhesives and Others. Based on Patch Type, the market is segmented into Drug-In-Adhesive, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches, Iontophoresis Patches and Vapour Patches. Based on Application, the market is segmented into Pain Management, Smoking Cessation, Hormone Replacement Therapy, Cardiovascular Disorder, Central Nervous System Disorder and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Viatris, Inc. (Mylan N.V.), Boehringer Ingelheim International GmbH, Endo International PLC, Bayer AG, Nitto Denko Corporation, Cipla Limited, Amneal Pharmaceuticals, Inc., Novartis AG, and AbbVie, Inc.
The market has witnessed remarkable growth and innovation in recent years, reshaping the landscape of pharmaceutical drug delivery. This market, driven by patient convenience, sustained drug release, and improved therapeutic outcomes, has become a pivotal component of the healthcare sector. Adopting transdermal patches has steadily risen across various healthcare domains, driven by several factors contributing to their attractiveness to healthcare providers and patients.
The aging population has also played a significant role in adopting transdermal patches. As the prevalence of chronic diseases rises among the elderly, there is a growing demand for therapeutic options that are not only effective but also user-friendly. These offer a solution to these demographic challenges by providing a convenient and patient-friendly method of drug administration. In addition to the ease of use, these provide controlled and sustained drug release, improving patient compliance and therapeutic outcomes.
North America is witnessing a significant increase in the incidence of chronic diseases such as diabetes, cardiovascular diseases, and chronic pain conditions. The aging population, sedentary lifestyles, and dietary patterns contribute to the higher prevalence of these conditions. Cardiovascular diseases, including hypertension and angina, are prevalent in North America. Therefore, growing chronic disease prevalence in North America is expected to help expand the regional market.
The US market dominated the North America Transdermal Patches Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,134.9 million by 2030. The Canada market is experiencing a CAGR of 6.2% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.3% during (2023 - 2030).
Based on End User, the market is segmented into Homecare Settings and Hospitals & Clinics. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on Adhesive Type, the market is segmented into Acrylic Adhesives, Silicone Adhesives, Hydrogel Adhesives and Others. Based on Patch Type, the market is segmented into Drug-In-Adhesive, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches, Iontophoresis Patches and Vapour Patches. Based on Application, the market is segmented into Pain Management, Smoking Cessation, Hormone Replacement Therapy, Cardiovascular Disorder, Central Nervous System Disorder and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Viatris, Inc. (Mylan N.V.), Boehringer Ingelheim International GmbH, Endo International PLC, Bayer AG, Nitto Denko Corporation, Cipla Limited, Amneal Pharmaceuticals, Inc., Novartis AG, and AbbVie, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User (Volume, Thousand Units, USD Billion, 2019-2030)- Homecare Settings
- Hospitals & Clinics
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Acrylic Adhesives
- Silicone Adhesives
- Hydrogel Adhesives
- Others
- Drug-In-Adhesive
- Matrix Patches
- Reservoir Membrane Patches
- Microneedle Patches
- Iontophoresis Patches
- Vapour Patches
- Pain Management
- Smoking Cessation
- Hormone Replacement Therapy
- Cardiovascular Disorder
- Central Nervous System Disorder
- Others
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
Companies Profiled- Johnson & Johnson
- Viatris, Inc. (Mylan N.V.)
- Boehringer Ingelheim International GmbH
- Endo International PLC
- Bayer AG
- Nitto Denko Corporation
- Cipla Limited
- Amneal Pharmaceuticals, Inc.
- Novartis AG
- AbbVie, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. North America Transdermal Patches Market by End User
Chapter 6. North America Transdermal Patches Market by Distribution Channel
Chapter 7. North America Transdermal Patches Market by Adhesive Type
Chapter 8. North America Transdermal Patches Market by Patch Type
Chapter 9. North America Transdermal Patches Market by Application
Chapter 10. North America Transdermal Patches Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Viatris, Inc. (Mylan N.V.)
- Boehringer Ingelheim International GmbH
- Endo International PLC
- Bayer AG
- Nitto Denko Corporation
- Cipla Limited
- Amneal Pharmaceuticals, Inc.
- Novartis AG
- AbbVie, Inc.
Methodology
LOADING...
